Of these factors, multicenter retrospective studies in Japan attempted to address whether patients with BRAF V600‐mutant melanoma, acral/mucosal subtypes of melanoma, and non‐acral/mucosal BRAF wild‐type melanoma should receive Nivo/Ipi upfront. Here, BRAF is linked to melanoma.